Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NOW stock price vs CI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CI's multiple
Needs CI P/E.
Implied fair value · at NOW's multiple
Needs NOW P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ServiceNow, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MICROSOFT CORP
NOW vs MSFT
ADOBE INC.
NOW vs ADBE
ORACLE CORP
NOW vs ORCL
Salesforce, Inc.
NOW vs CRM
INTERNATIONAL BUSINESS MACHINES CORP
NOW vs IBM
Paycom Software, Inc.
NOW vs PAYC
UNITEDHEALTH GROUP INC
NOW vs UNH
CVS HEALTH Corp
NOW vs CVS
HUMANA INC
NOW vs HUM
CENTENE CORP
NOW vs CNC
WEST PHARMACEUTICAL SERVICES INC
NOW vs WST
BAXTER INTERNATIONAL INC
NOW vs BAX
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NOW can sustain 20%+ revenue growth with high margins and justify a premium multiple over CI, then you can argue for holding the stock, but the data currently favors trimming or avoiding because NOW trades at 66.6x earnings and 8.7x sales versus CI’s much lower multiples.
NOW trades at a steep premium to CI across P/E, P/S, and EV-based multiples even though the implied price is far below the current price. CI-implied value of $21.01 versus the current price of $111.23 implies -81.1% downside, while NOW also sits above both the DCF range and the top of CI-implied range.
Supporting Metrics
